Barclays raised the price target for the Relay Therapeutics Inc. (NASDAQ:RLAY) stock to “an Equal weight”. The rating was released on September 30, 2022, according to finviz. The research report from Jefferies has initiated the stock to Underperform, with a price target set at $13. The stock was initiated by Berenberg, who disclosed in a research note on February 01, 2022, to Buy and set the price objective to $45. In their research brief published July 21, 2021, BofA Securities analysts initiated the Relay Therapeutics Inc. stock to Buy with a price target of $50.
The latest trade, Performances and Moving Averages give us the following Picture
The share price of Relay Therapeutics Inc. (NASDAQ:RLAY) dipped -1.11% to close Tuesday’s market session at $20.55, lower as compared to yesterday’s close. The stock price fluctuated between $20.41 and $21.79 throughout the trading session with the volume trading being 1639174 shares, which represented a significant variation when compared to the three months average volume of 1.29 million shares. The firm’s stock price fluctuated 0.49% within the last five trades and 38.66% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price increased 0.44% in the last 6 months and -0.39% was subtracted to its value over the previous 3 months. RLAY stock is trading at a margin of 20.12%, 16.44% and 0.37% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.
As of the close of trading, RLAY deals in the Healthcare domain. The stock is trading -41.88 percent below its 52-week high and 62.45 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is -23.37. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.
What Does Relay Therapeutics Inc.’s Profitability and Valuation Ratios Tell Us About the Stock?
The stock’s market cap achieved a total value of $2.44 billion as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. Forward price-to-earnings is calculated using predicted earnings for the next financial year’s P/E determination. The stock has achieved an effective Price-to-Sales Ratio of 1434.39 that mirrors the cost to be found for sales by the market. The firm managed a Price-to-Book ratio of 2.28, which equates the market value of a stock with its book value.
Is Insider Trading a Real Thing?
Patel Sanjiv, the President and CEO at Relay Therapeutics Inc. (RLAY) has sold 28,000 shares of firm on Jan 19 at a price of $20.02 against the total amount of $0.56 million. In another inside trade, Patel Sanjiv, President and CEO of Relay Therapeutics Inc. (NASDAQ:RLAY) sold 28,000 shares of the firm on Jan 18 for a total worth of $0.58 million at a price of $20.87. An inside trade which took place on Jan 17, President and CEO of Relay Therapeutics Inc. Patel Sanjiv sold 28,000 shares of firm against total price of $0.57 million at the cost of $20.23 per share.